The clinical impact of inhalational anesthetics extends far beyond the central nervous and cardiovascular systems. Every major organ system is affected to some degree by volatile agent exposure, and a clinician's ability to anticipate and manage organ-specific adverse effects is as important as understanding the desired anesthetic endpoints. This module addresses the pulmonary, hepatic, renal, skeletal muscle, and obstetrical effects of inhalational anesthetics, organ systems in which volatile agent pharmacology intersects with some of the most clinically consequential adverse effects in anesthetic practice, including malignant hyperthermia, halothane hepatitis, fluoride-induced nephropathy, and obstetric hemorrhage.12 The goal is not merely to enumerate toxicities but to provide a mechanistic understanding that enables rational agent selection and appropriate clinical vigilance.
Breathing Patterns All inhalational anesthetics produce dose-dependent respiratory depression through suppression of central respiratory drive in the medullary respiratory centers and through reduction of chemoreceptor responsiveness. The resulting breathing pattern at clinical maintenance concentrations is characteristically rapid and shallow: tidal volume is reduced while respiratory rate may actually increase, producing a net reduction in alveolar ventilation and progressive hypercapnia under spontaneous breathing conditions. This pattern is in contrast to opioid-induced respiratory depression, which primarily reduces respiratory rate while preserving tidal volume. At concentrations above 1 minimum alveolar concentration (MAC) under spontaneous ventilation, all volatile agents produce clinically significant hypoventilation requiring either acceptance of moderate hypercapnia, partial ventilatory assist, or controlled mechanical ventilation.1 Controlled mechanical ventilation, which normalizes PaCO2 by adjusting tidal volume and rate, is therefore standard practice during general anesthesia for most surgical procedures.
Ventilatory Responses to CO2 The ventilatory response to rising PaCO2 (hypercapnic ventilatory response) is progressively blunted by all inhalational anesthetics in a dose-dependent fashion. At 1 MAC, the slope of the CO2 response curve is reduced by approximately 50% from awake values; at 2 MAC, the response is nearly abolished. This means that the normal physiological drive to increase ventilation in response to rising CO2 is largely suppressed during anesthesia, and the anesthetized patient under spontaneous ventilation will not adequately compensate for the hypercapnia generated by reduced alveolar ventilation. The clinical consequence is that spontaneous ventilation under inhalational anesthesia inevitably results in hypercapnia unless anesthetic concentrations are kept below approximately 0.5 MAC, a level insufficient for most surgical procedures.12
Surgical Stimulation Surgical stimulation, including skin incision, peritoneal traction, and visceral manipulation, provides a powerful afferent stimulus that transiently augments ventilatory drive and can partially reverse the respiratory depression of volatile agents. This is most evident during light planes of anesthesia in patients breathing spontaneously, where surgical stimulation may produce an abrupt increase in respiratory rate and tidal volume. In addition to its respiratory effect, surgical stimulation activates the sympathetic nervous system and increases anesthetic requirements (consistent with the MAC concept), creating a dynamic relationship between surgical intensity and the required anesthetic depth throughout a case.
Mechanism of Anesthetic-Induced Ventilatory Depression The primary mechanism of anesthetic-induced ventilatory depression involves inhibition of central respiratory pattern generation in the medullary pre-Bötzinger complex, a rhythmogenic neuronal network responsible for generating the respiratory rhythm. Volatile agents enhance inhibitory gamma-aminobutyric acid type A (GABA-A) receptor activity and inhibit excitatory glutamate (N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)) receptor activity in these neurons, reducing the frequency and amplitude of inspiratory bursts. Peripheral chemoreceptor (carotid body) responsiveness to hypoxia and hypercapnia is also blunted, reducing the afferent drive to the respiratory centers from both hypoxic and hypercapnic stimuli.3 The net effect is a reduction in both the threshold and gain of central respiratory control.
Hypoxemia: Ventilatory Response The hypoxic ventilatory response, defined as the increase in ventilation triggered by falling PaO2 mediated primarily through the carotid body peripheral chemoreceptors, is exquisitely sensitive to inhalational anesthetics. Subanesthetic concentrations of volatile agents (as low as 0.1 MAC, concentrations encountered during recovery from anesthesia or during sedation,) substantially reduce the hypoxic ventilatory response by suppressing carotid body chemoreceptor activity. This depression of the hypoxic drive is clinically significant in the postoperative period: patients in the PACU with residual inhalational anesthetic in their tissues may fail to mount an adequate ventilatory response to hypoxemia and can desaturate silently without the expected compensatory tachypnea.3 This provides additional rationale for supplemental oxygen administration and pulse oximetry monitoring throughout the recovery period.
Airway Resistance: Volatile Anesthetics All volatile halogenated anesthetics produce bronchodilation through direct relaxation of bronchial smooth muscle, independent of any effect on the autonomic nervous system. The mechanism involves inhibition of intracellular calcium release and sensitization of smooth muscle contractile proteins to lower calcium concentrations. Sevoflurane and halothane are the most potent bronchodilators among the volatile agents; isoflurane and desflurane produce intermediate bronchodilation. Desflurane at high concentrations paradoxically may increase airway resistance in patients with reactive airways disease through its irritant effect on airway mucosa, triggering reflex bronchoconstriction, making sevoflurane the preferred agent in this population.4 The bronchodilator property of volatile agents has been exploited therapeutically in cases of refractory status asthmaticus unresponsive to conventional pharmacotherapy, where inhalational anesthesia with sevoflurane (administered via an anesthesia machine in the ICU) has been used as rescue therapy.
One-Lung Ventilation and Hypoxic Pulmonary Vasoconstriction All volatile halogenated anesthetics inhibit hypoxic pulmonary vasoconstriction (HPV) in a dose-dependent fashion. HPV is the physiological reflex by which pulmonary arterioles constrict in response to alveolar hypoxia, diverting blood flow away from poorly ventilated lung regions to better-ventilated regions, thereby preserving arterial oxygenation. During one-lung ventilation (OLV) for thoracic surgery, the dependent lung is ventilated while the operative lung is collapsed; HPV in the collapsed lung reduces but does not eliminate the shunt fraction, typically limiting shunt to approximately 20 to 30% of cardiac output during OLV in the absence of anesthetic HPV inhibition.4
Volatile agents inhibit HPV in proportion to their inspired concentration. At 1 MAC, HPV inhibition is substantial and shunt fraction increases accordingly, contributing to intraoperative hypoxemia during OLV. Propofol, used as the hypnotic agent in TIVA, does not inhibit HPV and is therefore the preferred maintenance agent for thoracic surgery cases requiring OLV, particularly where preoperative pulmonary function is marginal. When volatile agents are used for OLV cases, concentrations should be kept as low as clinically feasible, generally at or below 0.5 MAC, supplemented by opioid and adjuvant agents to achieve adequate depth. Practical strategies to manage hypoxemia during OLV include applying continuous positive airway pressure (CPAP) of 5 to 10 cmH2O to the operative lung (improving oxygenation without impairing surgical access), using recruitment maneuvers on the dependent ventilated lung, and intermittent two-lung ventilation if desaturation is refractory.1
Volatile Anesthetics and Drug Clearance General anesthesia produces significant reductions in hepatic blood flow, which directly impairs the clearance of drugs with high hepatic extraction ratios (flow-dependent drugs). Hepatic blood flow is reduced by all volatile agents, partly through reduced cardiac output and splanchnic vasoconstriction, and partly through the reduction in portal venous flow that accompanies decreased intestinal motility under anesthesia. The magnitude of hepatic blood flow reduction is greatest with halothane (which also reduces portal venous flow directly) and somewhat less with isoflurane and sevoflurane, which tend to preserve hepatic arterial flow through autoregulatory mechanisms.5 For drugs with high hepatic extraction ratios (propranolol, morphine, lidocaine, many opioids), reduced hepatic blood flow during anesthesia can significantly reduce clearance and prolong drug effect, a consideration in managing postoperative opioid requirements and residual drug levels in the immediate postoperative period.
Hepatotoxicity Overview Volatile anesthetic-induced hepatotoxicity occurs through two distinct mechanisms. The first is direct hepatotoxicity from anesthesia-induced reduction in hepatic oxygen delivery, producing zone 3 (centrilobular) necrosis in proportion to the degree of hypoxia; this is a pharmacologically non-specific effect of any anesthetic that reduces hepatic blood flow and oxygen delivery, and is most relevant in patients with pre-existing hepatic disease or cardiovascular compromise. The second mechanism, and the one responsible for the clinically important agent-specific hepatotoxicity of halothane, is immune-mediated hepatitis resulting from trifluoroacetylation of hepatic proteins by reactive oxidative metabolites of CYP2E1 (cytochrome P450 2E1)-mediated halogenated agent metabolism.56 The degree of hepatic protein trifluoroacetylation is directly proportional to the fraction of the agent that undergoes this metabolic pathway: halothane (approximately 20%) > enflurane (approximately 2–5%) > isoflurane (approximately 0.2%) > desflurane (<0.02%). Sevoflurane undergoes a quantitatively similar degree of hepatic metabolism (~3–5%) but via a pathway that generates hexafluoroisopropanol (HFIP) rather than trifluoroacetylated proteins, conferring a distinct hepatotoxic mechanism and risk profile.
Hepatotoxicity Overview: Halothane (Fluothane) Halothane produces two clinically distinct forms of hepatic dysfunction. Type I halothane hepatotoxicity is a mild, self-limiting transaminase elevation observed in up to 20–30% of patients after halothane exposure, attributed to anesthesia-related hepatic oxygen supply-demand imbalance and direct halothane-induced lipid peroxidation in hepatocytes. It is subclinical, resolves spontaneously, and has no serious clinical sequelae. Type II halothane hepatotoxicity, halothane hepatitis, is a rare but frequently fatal immune-mediated hepatic necrosis.5
Halothane Hepatitis Halothane hepatitis occurs in approximately 1 in 35,000 halothane exposures in adults (the incidence is lower in children). It is a classic example of immune-mediated drug-induced liver injury (DILI) mediated by the following sequence of events: CYP2E1 oxidizes approximately 20% of absorbed halothane to trifluoroacetyl chloride, a highly reactive acylating species that covalently modifies lysine residues on hepatocyte endoplasmic reticulum proteins, generating trifluoroacetylated neoantigens.56 In susceptible individuals, those with a particular genetic predisposition likely involving human leukocyte antigen DR (HLA-DR) haplotypes, these neoantigens trigger a cytotoxic T-lymphocyte and antibody-mediated immune response targeting hepatocytes. The resulting immune attack produces massive or submassive hepatic necrosis clinically and histologically indistinguishable from fulminant viral hepatitis.
The clinical presentation of halothane hepatitis is characterized by fever (typically appearing 3–7 days after exposure), followed by jaundice, markedly elevated transaminases (ALT and AST in the thousands), and in severe cases progression to fulminant hepatic failure with coagulopathy, encephalopathy, and death. Serum antibodies against trifluoroacetylated hepatocyte proteins can be detected in affected patients and provide diagnostic confirmation, though they are not routinely measured.5 Risk factors for halothane hepatitis include female sex, obesity, middle age, multiple prior halothane exposures (particularly with short intervals between exposures), and family history of halothane hepatitis. Re-exposure to halothane after a sensitizing exposure dramatically increases the risk of halothane hepatitis and is absolutely contraindicated. In current anesthetic practice in high-resource settings, halothane has largely been replaced by agents with far lower trifluoroacetylation potential, and halothane hepatitis has correspondingly become rare.
Enflurane (Ethrane), Isoflurane (Forane), and Desflurane (Suprane) Enflurane, isoflurane, and desflurane undergo trifluoroacetylation of hepatic proteins through the same CYP2E1 pathway as halothane, but at dramatically lower metabolic fractions (2–5%, 0.2%, and <0.02% respectively). Cross-reactive antibodies from prior halothane sensitization can theoretically recognize trifluoroacetylated proteins generated by these agents, making immune-mediated hepatitis a theoretical risk, particularly with enflurane and isoflurane. Rare cases of isoflurane-associated hepatitis resembling halothane hepatitis have been reported, particularly in patients with prior halothane exposure, confirming that cross-sensitization occurs.6 Desflurane's near-negligible trifluoroacetylation means that clinically significant hepatitis attributable to desflurane is exceptionally rare. For practical clinical purposes, in a patient with documented prior halothane hepatitis, the preference is for desflurane (lowest risk) or sevoflurane (which does not generate trifluoroacetylated proteins) as volatile agents, or TIVA avoidance of volatile agents entirely.
Neuromuscular Junction Volatile anesthetics produce dose-dependent potentiation of nondepolarizing neuromuscular blockade. At 1 minimum alveolar concentration (MAC), most volatile agents reduce the required dose of a nondepolarizing neuromuscular blocker by approximately 20–30% compared to balanced IV anesthesia with propofol and opioids.7 This interaction occurs through multiple mechanisms: direct inhibition of nicotinic acetylcholine receptor channel opening by volatile agents, presynaptic reduction of acetylcholine release, and potentiation of the blocking effect of nondepolarizing agents at the postjunctional receptor. The clinical implication is that neuromuscular blockade monitoring (train-of-four) is essential during volatile agent anesthesia, as standard doses of nondepolarizing agents may produce more profound and more prolonged blockade than anticipated from prior experience with IV techniques. Conversely, at the time of reversal, the residual volatile agent may continue to potentiate the block and impair reversal; ensuring adequate gas elimination during emergence is important for successful neostigmine-mediated reversal.
Malignant Hyperthermia and Volatile Anesthetics Malignant hyperthermia (MH) is a potentially lethal pharmacogenetic disorder of skeletal muscle calcium homeostasis triggered by exposure to volatile halogenated anesthetics and to succinylcholine. It is caused by mutations in the ryanodine receptor type 1 (RYR1) gene, and less commonly voltage-dependent calcium channel subunit alpha-1S gene (CACNA1S) and several other loci, which produce a gain-of-function defect in the sarcoplasmic reticulum calcium release channel.8 In susceptible individuals, exposure to a triggering agent causes uncontrolled release of calcium from the sarcoplasmic reticulum into the myoplasm, resulting in sustained, uncoordinated skeletal muscle contracture, massive hypermetabolism, and a clinical syndrome characterized by rapidly rising end-tidal CO2 (the earliest and most sensitive sign), tachycardia, muscle rigidity (masseter spasm initially, generalized rigidity in full crisis), hyperthermia (temperature may rise at 1–2°C per minute, reaching values above 40–41°C), metabolic and respiratory acidosis, rhabdomyolysis, hyperkalaemia, and cardiovascular collapse.
All volatile halogenated agents, specifically halothane, isoflurane, sevoflurane, desflurane, and enflurane, are triggering agents for MH. Nitrous oxide is not an MH trigger. The clinical presentation may be fulminant within minutes of exposure or may develop gradually over 30–60 minutes.8
Treatment of MH requires immediate discontinuation of all triggering agents, which in the operating room means stopping the volatile anesthetic immediately, flushing the circuit with 10 L/min of 100% oxygen to wash out residual volatile agent, and switching to a non-triggering technique (propofol, midazolam, opioids, nondepolarizing agents). The specific antidote is dantrolene sodium, a hydantoin derivative that inhibits calcium release from the sarcoplasmic reticulum by binding to the RYR1 receptor and stabilizing it in the closed state. Dantrolene must be administered as early as possible; the initial dose is 2.5 mg/kg IV, repeated every 5 minutes as needed until the hypermetabolic crisis resolves; total doses of 10 mg/kg or higher may be required in severe cases.8 Supportive measures include active cooling (iced saline lavage, cooling blankets, ice packs to major vessels), sodium bicarbonate for metabolic acidosis, calcium and insulin-glucose for hyperkalemia, antiarrhythmic agents (amiodarone, avoiding calcium channel blockers which interact adversely with dantrolene), and aggressive IV fluid resuscitation to protect the kidneys from myoglobinuria. Dantrolene infusion is continued at 1 mg/kg every 4–6 hours for at least 24 hours after the acute crisis to prevent recurrence.
Patients known or suspected to be MH-susceptible should receive a non-triggering anesthetic (TIVA with propofol, opioids, and nondepolarizing agents, with nitrous oxide permitted if needed), and the operating room should be prepared with a clean (purged) anesthesia machine or a dedicated MH-safe machine. Dantrolene must be immediately available (at least 36 vials of lyophilized dantrolene, yielding 720 mg). Family members of affected patients should be counseled regarding the autosomal dominant inheritance of MH susceptibility, and referred for genetic testing and/or caffeine-halothane contracture testing (the diagnostic gold standard) where available.
Malignant Hyperthermia: Genetics and Emergency Planning MH susceptibility is inherited as an autosomal dominant trait with variable penetrance. Mutations in RYR1 account for approximately 70% of MH-susceptible families; mutations in CACNA1S account for approximately 1%. More than 400 causative RYR1 variants have been identified, and the heterogeneity of causative mutations means that a negative targeted genetic test does not exclude MH susceptibility in a member of an affected family. The in vitro caffeine-halothane contracture test (CHCT), performed on fresh skeletal muscle biopsy from the vastus lateralis, remains the diagnostic gold standard, with sensitivity of approximately 99% and specificity of approximately 94%.8 Testing is available at designated centers affiliated with the Malignant Hyperthermia Association of the United States (MHAUS) and equivalent international registries. First-degree relatives of a confirmed MH-susceptible individual have a 50% prior probability of susceptibility; all should receive non-triggering anesthesia and be referred for CHCT or genetic counseling prior to any elective surgical procedure.
When an MH-susceptible patient requires emergency surgery and a fully purged anesthesia machine is unavailable, the circuit and carbon dioxide absorbent must be changed, the machine should be flushed with 10 L/min of 100% oxygen for a minimum of 20 minutes (or per the manufacturer-specific purge protocol), and activated charcoal filters should be placed on the inspiratory and expiratory limbs of the breathing circuit if available. TIVA with propofol, remifentanil, and a nondepolarizing neuromuscular blocking agent provides safe anesthesia in MH-susceptible patients without requiring a dedicated MH-safe machine. Dantrolene (at least 36 vials, 720 mg) must be present in the operating room suite before the case begins regardless of technique, as succinylcholine used emergently for airway rescue remains a triggering risk.8
Volatile Anesthetics: Obstetrical Effects All volatile halogenated anesthetics cross the placenta readily by passive diffusion, as they are small, lipid-soluble, non-ionized molecules. Fetal blood concentrations approach maternal concentrations within minutes of maternal induction, making the fetal drug exposure a function of time from induction to delivery. This pharmacokinetic fact has historically driven the obstetric anesthesia practice of minimizing the induction-to-delivery interval during cesarean section under general anesthesia.1 The primary concern is neonatal respiratory depression from transplacental volatile anesthetic accumulation in the fetus; however, at the concentrations used for general anesthesia during cesarean section (typically 0.5–0.75 minimum alveolar concentration (MAC) of a volatile agent combined with 50% nitrous oxide), and with a rapid induction-to-delivery interval, neonatal depression is generally mild and responsive to standard neonatal resuscitation.
Uterine relaxation is the most clinically important direct effect of volatile anesthetics on the obstetric patient. All volatile agents produce dose-dependent relaxation of uterine smooth muscle, reducing myometrial contractility in proportion to the inspired concentration. At concentrations used for induction (2–3 MAC transiently during inhalational induction), significant uterine relaxation occurs rapidly. At maintenance concentrations of 0.5–1.0 MAC during cesarean section under general anesthesia, uterine atony and increased postpartum hemorrhage risk are real but manageable concerns, particularly when combined with prompt oxytocin administration after delivery. At concentrations above 1.5 MAC, uterine atony becomes severe and can produce life-threatening hemorrhage.1 This concentration-response relationship explains the clinical guideline of maintaining volatile agent concentrations at or below 0.5–0.75 MAC during general anesthesia for cesarean section, supplemented by nitrous oxide and opioids to achieve adequate depth without unacceptable uterine relaxation.
The uterine relaxant property of volatile anesthetics is not always undesirable. In specific obstetric emergencies requiring deliberate uterine relaxation, such as retained placenta requiring manual removal, uterine inversion requiring manual reduction, or second twin delivery requiring external version, inhalational anesthesia with a volatile agent at concentrations sufficient to produce reliable uterine relaxation is the most rapidly titratable pharmacological approach. Nitroglycerin (100–200 mcg IV) provides an alternative rapid uterine relaxant in these settings without the systemic anesthetic effects of volatile agents.
Nitrous Oxide: Obstetrical Effects Nitrous oxide at 50% inspired concentration is widely used in some countries for labor analgesia (Entonox, a 50:50 N2O:O2 mixture), providing moderate analgesia for contractions through N-methyl-D-aspartate (NMDA) receptor antagonism and endogenous opioid mechanisms without producing loss of consciousness at this concentration.2 It produces minimal uterine relaxation at concentrations used for labor analgesia and does not significantly impair uterine contractility at doses below 50%. At higher concentrations used as part of general anesthesia for cesarean section (50–70% combined with a volatile agent), nitrous oxide's effects on the uterus are modest relative to the volatile agent contribution. The primary concern with nitrous oxide in obstetrics relates to its inhibition of methionine synthase (discussed in Part 2): repeated or prolonged exposure in neonates or in mothers with marginal vitamin B12 status raises theoretical concerns about folate pathway impairment, though clinically significant neonatal complications from brief intrapartum N2O exposure have not been convincingly demonstrated.2 Nitrous oxide freely crosses the placenta; brief exposure during delivery produces measurable neonatal blood levels, but neonatal outcomes with standard obstetric nitrous oxide use are not significantly impaired compared to non-nitrous-oxide techniques.
General Anesthesia for Cesarean Section: The Complete Clinical Scenario General anesthesia (GA) for cesarean section is now reserved for situations where neuraxial anesthesia (spinal or epidural) is contraindicated, has failed, or where the urgency of delivery does not permit the time required for neuraxial block onset. The parturient presents a unique combination of anesthetic risk factors that must be systematically addressed: full-stomach aspiration risk (progesterone-mediated lower esophageal sphincter relaxation, delayed gastric emptying, increased intra-abdominal pressure), anticipated difficult airway (airway edema of pregnancy, breast enlargement limiting laryngoscope handle manipulation, rapid oxygen desaturation due to reduced functional residual capacity and increased oxygen consumption), and the requirement for uterine preservation of the fetus.1
The induction sequence for obstetric GA follows a modified rapid sequence approach. Aspiration prophylaxis is administered prior to induction: sodium citrate 30 mL orally immediately before induction (to neutralize existing gastric acid), a histamine H2 receptor antagonist or proton pump inhibitor given at least 30 minutes before (to reduce ongoing acid production), and metoclopramide 10 mg IV (to accelerate gastric emptying and increase lower esophageal sphincter tone). Pre-oxygenation with 100% oxygen for 3 minutes of tidal volume breathing (or 4 maximal-capacity breaths over 30 seconds in urgent cases) is performed prior to induction. Propofol (1.5 to 2.0 mg/kg IV) or thiopental (4 to 5 mg/kg IV where available) provides induction, followed immediately by succinylcholine (1.5 mg/kg IV) for rapid sequence intubation with cricoid pressure. Rocuronium 1.2 mg/kg is an acceptable alternative when succinylcholine is contraindicated, with sugammadex 16 mg/kg available for reversal if the airway cannot be secured.1
Failed intubation in the obstetric patient is a declared emergency. The Difficult Airway Society obstetric guidelines recommend a structured response: declare failed intubation, maintain oxygenation, call for help, and decide whether to wake the patient (if surgery is not immediately life-saving) or proceed with a supraglottic airway device (laryngeal mask airway) for oxygenation and airway maintenance. Neonatal assessment uses Apgar scores at 1 and 5 minutes; scores below 7 at 1 minute warrant active resuscitation. Neonates born under volatile agent anesthesia may require additional resuscitative support due to transplacental drug accumulation, and the neonatal team should be present and prepared. After delivery, the volatile agent concentration is typically reduced to 0.5 to 0.75 MAC and an opioid is added (since pre-delivery opioid is withheld to avoid neonatal respiratory depression), oxytocin is administered to promote uterine contraction, and the balanced anesthetic is maintained for the remainder of the procedure.12
Overview Volatile anesthetics reduce renal blood flow and glomerular filtration rate (GFR) in proportion to their effects on cardiac output and mean arterial pressure, and through direct renal vasoconstriction. These hemodynamic effects are transient and functionally insignificant in patients with normal renal reserve; they reverse with emergence. In patients with pre-existing renal impairment, however, any reduction in renal perfusion during anesthesia may contribute to perioperative acute kidney injury, particularly when combined with surgical blood loss, nephrotoxic drug exposure (NSAIDs, contrast agents, aminoglycosides), or prolonged hypotension.9 Beyond these hemodynamic effects, specific volatile agents carry agent-specific nephrotoxic risks related to their metabolic byproducts.
Fluoride-Induced Renal Toxicity The mechanism of fluoride-induced renal toxicity was first characterized with methoxyflurane, a now-discontinued volatile agent that underwent approximately 50% hepatic and intrarenal metabolism, generating very high serum inorganic fluoride concentrations (>50 μmol/L, the threshold associated with renal tubular toxicity). Inorganic fluoride ion at these concentrations causes a vasopressin-resistant (nephrogenic) diabetes insipidus, a high-output renal failure syndrome characterized by inability to concentrate urine despite adequate vasopressin levels, reflecting fluoride toxicity to the thick ascending limb of the loop of Henle.9 Enflurane generates serum fluoride concentrations in the range of 20–30 μmol/L after prolonged administration, approaching but generally not exceeding the toxic threshold, and is associated with a mild, subclinical reduction in urinary concentrating ability in some patients, particularly those with pre-existing renal impairment or those on drugs that inhibit enflurane metabolism (isoniazid increases CYP2E1 (cytochrome P450 2E1) expression).
Sevoflurane can generate serum fluoride concentrations transiently above 50 μmol/L due to its 3–5% hepatic metabolism. However, unlike methoxyflurane, sevoflurane does not appear to cause clinically significant nephrotoxicity at these fluoride levels. The explanation lies in the organ distribution of metabolism: methoxyflurane was substantially metabolized within the kidney itself, generating high local intrarenal fluoride concentrations at the site of tubular toxicity. Sevoflurane's metabolism occurs primarily in the liver, and renal CYP2E1-mediated metabolism of sevoflurane is minimal, so intrarenal fluoride generation is insufficient to produce tubular injury despite elevated systemic fluoride levels.9 Multiple prospective clinical trials of sevoflurane anesthesia at low fresh gas flows, including in patients with pre-existing renal impairment, have failed to demonstrate a significant increase in clinically meaningful nephrotoxicity compared to isoflurane or desflurane. The fluoride threshold concept from methoxyflurane does not straightforwardly translate to sevoflurane nephrotoxicity risk.
Vinyl Halide Nephrotoxicity Compound A (fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether) is a vinyl halide generated by the degradation of sevoflurane by carbon dioxide absorbents under conditions of low fresh gas flow and elevated soda lime temperature. In rats, compound A is nephrotoxic at concentrations as low as 25–50 ppm, producing corticomedullary tubular necrosis through mechanisms involving glutathione conjugation and subsequent bioactivation of reactive sulfur conjugates.9 In humans, the metabolism of compound A follows a different pathway: the rat-specific cysteine conjugate beta-lyase pathway responsible for nephrotoxic activation is quantitatively much less active in humans, and clinically significant compound A nephrotoxicity has not been demonstrated in multiple well-designed clinical trials, even at low fresh gas flows during prolonged sevoflurane anesthesia. Nevertheless, regulatory agencies in several jurisdictions have recommended maintenance of fresh gas flows ≥2 L/min with sevoflurane to limit compound A exposure, and caution is warranted in patients with pre-existing chronic kidney disease undergoing prolonged procedures under low-flow sevoflurane anesthesia, where compound A concentrations and the duration of exposure are both maximized.9 The ongoing scientific and regulatory debate around compound A nephrotoxicity illustrates the challenges of translating animal toxicology data to human clinical risk.
Miller RD, ed. Miller's Anesthesia. 8th ed. Philadelphia: Elsevier; 2015. Chapters 27, 77.
Enkin M, Renfrew MJ, Neilson J, et al. A Guide to Effective Care in Pregnancy and Childbirth. 3rd ed. Oxford: Oxford University Press; 2000. [Nitrous oxide in labor.]
Dahan A, Sarton E, Teppema L, Olievier C. Sex-related differences in the influence of morphine on ventilatory control in humans. Anesthesiology. 1998;88(4):903–913. [Ventilatory control and anesthesia.]
Goff MJ, Arain SR, Ficke DJ, Uhrich TD, Ebert TJ. Absence of bronchodilation during desflurane anesthesia: a comparison to sevoflurane and thiopental. Anesthesiology. 2000;93(2):404–408.
Kenna JG, Neuberger J, Mieli-Vergani G, Mowat AP, Williams R. Halothane hepatitis in children. Br Med J (Clin Res Ed). 1987;294(6581):1209–1211.
Njoku D, Laster MJ, Gong DH, Eger EI 2nd, Reed GF, Martin JL. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg. 1997;84(1):173–178.
Wulf H, Ledowski T, Linstedt U, Proppe D, Sitzlack D. Neuromuscular blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anaesthesia. Can J Anaesth. 1998;45(6):526–532.
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93
doi:10.1186/s13023-015-0310-1Kharasch ED. Sevoflurane and renal toxicity. Curr Opin Anaesthesiol. 1998;11(4):377–381.
Flood P, Rathmell JP, Shafer SL, eds. Stoelting's Pharmacology and Physiology in Anesthetic Practice. 5th ed. Philadelphia: Wolters Kluwer; 2015.
Stoelting RK, Hillier SC. Pharmacology and Physiology in Anesthetic Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
Eger EI 2nd. Anesthetic Uptake and Action. Baltimore: Williams & Wilkins; 1974.
Mhyre JM, Healy D. The unanticipated difficult intubation in obstetrics. Anesth Analg. 2011;112(3):648–652. doi:10.1213/ANE.0b013e31820a91a5
Mushambi MC, Kinsella SM, Popat M, et al. Obstetric Anaesthetists' Association and Difficult Airway Society guidelines for the management of difficult and failed tracheal intubation in obstetrics. Anaesthesia. 2015;70(11):1286–1306. doi:10.1111/anae.13260